文献速递泌尿男性生殖肿瘤

晚期非透明细胞肾细胞癌患者一线免疫检查点抑制剂治疗的结局

Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
PubMed 文献 · Eur J Cancer · 2022-06-16

基于IMDC数据库的回顾性分析纳入1145例转移性非透明细胞肾细胞癌(nccRCC)患者,比较一线ICI为主治疗、VEGF抑制剂单药与mTOR抑制剂单药的结局;ICI组中位OS为28.6个月,校正后OS风险比相对VEGF为0.57、相对mTOR为0.50,作者结论认为一线ICI为主治疗似乎与OS改善相关,并应在前瞻性随机试验中确认。

要点

  • nccRCC最常见亚型为乳头状RCC(54.9%),一线VEGF单药占74.3%,ICI为主治疗仅占10.7%。
  • ICI组中位OS 28.6个月,VEGF组16.4个月,mTOR组12.2个月。
  • 校正IMDC风险组、组织学亚型与年龄后,ICI相对VEGF的OS HR 0.57(95%CI 0.42-0.78,p<0.0001),相对mTOR的OS HR 0.50(95%CI 0.36-0.71,p<0.0001)。

核心结论

  • 在晚期nccRCC中,一线ICI为主治疗与VEGF及mTOR靶向治疗相比似乎与OS改善相关。
  • 作者指出这些结果应在前瞻性随机试验中确认。

研究设计与样本

  • 利用国际转移性RCC数据库联盟(IMDC)开展的回顾性分析,评估晚期nccRCC患者的结局。
  • 共纳入1145例转移性nccRCC患者,按一线治疗分为ICI为主治疗(单药或联合)、VEGF抑制剂单药、mTOR抑制剂单药三组。
  • 主要结局为总生存(OS),次要结局为至治疗失败时间(TTF)和客观缓解率(ORR);采用Kaplan-Meier法比较OS与TTF,采用Cox比例风险模型校正预后协变量。

主要发现

  • 最常见亚型为乳头状RCC(54.9%);一线治疗中74.3%接受VEGF单药、15%接受mTOR单药、10.7%接受ICI为主治疗。
  • ICI组中位OS为28.6个月,VEGF组为16.4个月,mTOR组为12.2个月。
  • ICI组中位TTF为6.9个月,VEGF组为5.0个月,mTOR组为3.9个月。
  • ORR在ICI组为27.2%,VEGF组为14.5%,mTOR组为9%。
  • 校正IMDC风险组、组织学亚型与年龄后,ICI相对VEGF的OS HR为0.57(95%CI 0.42-0.78,p<0.0001),ICI相对mTOR的OS HR为0.50(95%CI 0.36-0.71,p<0.0001)。

临床怎么用

  • 作者结论认为,在晚期nccRCC中一线ICI为主治疗与VEGF及mTOR靶向治疗相比似乎与OS改善相关。
  • 作者指出这些结果应在前瞻性随机试验中确认。

局限性

  • 原文为回顾性分析。
  • 作者指出这些结果应在前瞻性随机试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICI) have demonstrated impressive activity in metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment options for patients with advanced disease. Data supporting the effectiveness of ICI-based therapy in advanced non-clear cell RCC (nccRCC) is more limited. METHODS: We performed a retrospective analysis using the International Metastatic RCC Database Consortium (IMDC) to evaluate the outcomes of patients with advanced nccRCC. Patients were classified into three groups based on first-line therapy: ICI-based therapy (monotherapy or combination), vascular endothelial growth factor (VEGF) inhibitor monotherapy, or mammalian target of rapamycin (mTOR) inhibitor monotherapy. The primary outcome was overall survival (OS). Secondary outcomes were time to treatment failure (TTF) and objective response rate (ORR). We used the Kaplan-Meier method to compare OS and TTF between treatment groups and Cox proportional hazards models to adjust for prognostic covariates. RESULTS: We identified a total of 1145 patients with metastatic nccRCC. The most common subtype was papillary RCC (54.9%). For first-line therapy, 74.3% received VEGF monotherapy, 15% received mTOR monotherapy, and 10.7% received ICI-based therapy. Median OS in the ICI group was 28.6 months, versus 16.4 months in the VEGF group and 12.2 months in the mTOR group. Median TTF in the ICI group was 6.9 months, versus 5.0 months in the VEGF group and 3.9 months in the mTOR group. ORR was 27.2% in the ICI group, 14.5% in the VEGF group, and 9% in the mTOR group. After adjusting for the IMDC risk group, histological subtype, and age, the hazard ratio for OS was 0.57 (95% CI 0.42-0.78, p < 0.0001) for ICI versus VEGF and 0.50 (95% CI 0.36-0.71, p < 0.0001) for ICI versus mTOR. CONCLUSIONS: In advanced nccRCC, first-line ICI-based treatment appears to be associated with improved OS compared to VEGF and mTOR targeted therapy. These results should be confirmed in prospective randomised trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Graham J, Wells JC, Dudani S, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022. PMID: 35717820. doi:10.1016/j.ejca.2022.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。